Correction to: Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries.
Resource Type
Authors
Badio M; Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia.; Lhomme E; Univ. Bordeaux, Inserm, Bordeaux Population Health Research, Center, UMR 1219, CHU Bordeaux, CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, F-33000, Bordeaux, France.; Kieh M; Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia.; Beavogui AH; Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah, Mafèrinyah, Guinea.; Kennedy SB; Partnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia.; Doumbia S; University of Sciences, Technique and Technology of Bamako, Bamako, Mali.; Leigh B; College of Medicine and Allied Health Sciences (COMAHS), University of Sierra Leone, Freetown, Sierra Leone.; Sow SO; Centre pour le Développement des Vaccins, Bamako, Mali.; Diallo A; INSERM, Pôle de Recherche Clinique, 75013, Paris, France.; Fusco D; INSERM, Pôle de Recherche Clinique, 75013, Paris, France.; Kirchoff M; National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.; Termote M; Univ. Bordeaux, Inserm, Bordeaux Population Health Research, Center, UMR 1219, CHU Bordeaux, CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, F-33000, Bordeaux, France.; Vatrinet R; REACTing, Institut Thématique Immunologie, Inflammation, Infectiologie et Microbiologie, Inserm, Paris, France.; Wentworth D; Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.; Esperou H; INSERM, Pôle de Recherche Clinique, 75013, Paris, France.; Lane HC; National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.; Pierson J; National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA.; Watson-Jones D; London School of Hygiene & Tropical Medicine, London, UK.; Roy C; Univ. Bordeaux, Inserm, Bordeaux Population Health Research, Center, UMR 1219, CHU Bordeaux, CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, F-33000, Bordeaux, France.; D'Ortenzio E; REACTing, Institut Thématique Immunologie, Inflammation, Infectiologie et Microbiologie, Inserm, Paris, France.; AP-HP, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales, F-75018, Paris, France.; Greenwood B; London School of Hygiene & Tropical Medicine, London, UK.; Chêne G; Univ. Bordeaux, Inserm, Bordeaux Population Health Research, Center, UMR 1219, CHU Bordeaux, CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, F-33000, Bordeaux, France.; Richer L; Univ. Bordeaux, Inserm, Bordeaux Population Health Research, Center, UMR 1219, CHU Bordeaux, CIC 1401, EUCLID/F-CRIN Clinical Trials Platform, F-33000, Bordeaux, France.; Neaton JD; Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.; Yazdanpanah Y; REACTing, Institut Thématique Immunologie, Inflammation, Infectiologie et Microbiologie, Inserm, Paris, France. yazdan.yazdanpanah@aphp.fr.; AP-HP, Hôpital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales, F-75018, Paris, France. yazdan.yazdanpanah@aphp.fr.
Source
Publisher: BioMed Central Country of Publication: England NLM ID: 101263253 Publication Model: Electronic Cited Medium: Internet ISSN: 1745-6215 (Electronic) Linking ISSN: 17456215 NLM ISO Abbreviation: Trials Subsets: PubMed not MEDLINE; MEDLINE